I just posted the third of a four part interview with Dr. Byrd where he discusses some of the details of what we know about ibrutinib therapy so far. This is a deeper look at the complications, combinations, CAR-T and more than in my prior posts so if you are new to the subject I suggest you see the first two parts of the interview with Dr, Byrd and the interviews with Dr. Pagel at the same meeting. They all can be found at bkoffman.blogspot.com
ASH 2012 Interviews Part 3 Dr. John Byrd on Ib... - CLL Support
ASH 2012 Interviews Part 3 Dr. John Byrd on Ibrutinib
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Hi I have watched all the videos with great hope. Enjoy your holiday in Ireland, hope the weather isn't too bad. Best wishes.
Not what you're looking for?
You may also like...
ASH 2012 Interview: Dr Jeff Sharman \"Why New CLL Treatments Supersede FCR\"
Patient Power, asks Dr Sharman to discuss whether emerging therapies will replace FCR....
ASH 2012 Ibrutinib Press Conference
http://www.patientpower.info/video/results-suggest-a-potential-breakthrough-in-cll?autoplay=1
ASH 2013: INTERVIEW WITH DR. FURMAN RE: IDELALISIB
last blog post ( http://bkoffman.blogspot.com ), I have a short and interesting video interview...
ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
work. In the first part of my interview with Dr. Kipps at ASH 2018, he discusses resistance and how...
ASH 2016: Dr. Mato on real world data on ibrutinib
Hi,
This week I'm posting an interview that I had with Dr. Anthony Mato from U Penn when we talked...